Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
. These results suggest that PD-L1 on EVs may be another mechanism for glioblastoma to suppress antitumor immunity and support the potential of EVs as biomarkers in tumor patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“EVs derived from a variety of tumor types including melanoma, glioblastoma, breast, and head and neck cancer contain functional PD-L1 on their surface (Chen et al., 2018; Ricklefs et al., 2018; Theodoraki et al., 2018).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Ricklefs et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Causal analysis approaches in Ingenuity Pathway Analysis
Krämer, A., Green, J., Pollard, J., & Tugendreich, S. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt703 · Cited by 5,724
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294 · cited 1×
“One of themost prominent molecules used by tumor cells to engage T cell immune checkpoints is programmed death ligand 1 (PD-L1) (9, 10).”
BackgroundSelf-citationSingle-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
Patel, A. P., Tirosh, I., Trombetta, J. J., Shalek, A. K., Gillespie, S. M., Wakimoto, H., Cahill, D. P., Nahed, B. V., Curry, W. T., Martuza, R. L., et al. (2014) · Science · doi:10.1126/science.1254257 · Cited by 5,063
Cited by
Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
Chen, G., Huang, A. C., Zhang, W., Zhang, G., Wu, M., Xu, W., Yu, Z., Yang, J., Wang, B., Sun, H., et al. (2018) · Nature · doi:10.1038/s41586-018-0392-8 · Cited by 2,813
Extracellular vesicles as a next-generation drug delivery platform
Herrmann, I. K., Wood, M. J. A., & Fuhrmann, G. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00931-2 · Cited by 1,948
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648
Current and future perspectives of liquid biopsies in genomics-driven oncology
Heitzer, E., Haque, I. S., Roberts, C. E. S., & Speicher, M. R. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-018-0071-5 · Cited by 1,557
Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory
Poggio, M., Hu, T., Pai, C.-C., Chu, B., Belair, C. D., Chang, A., Montabana, E., Lang, U. E., Fu, Q., Fong, L., et al. (2019) · Cell · doi:10.1016/j.cell.2019.02.016 · Cited by 1,376
“Furthermore, EV PD-L1 levels have been associated with tumor progression (Chen et al., 2018; Ricklefs et al., 2018; Theodoraki et al., 2018; Yang et al., 2018).”
BackgroundAdvances in therapeutic applications of extracellular vesicles
Wiklander, O. P. B., Brennan, M. Á., Lötvall, J., Breakefield, X. O., & EL Andaloussi, S. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav8521 · Cited by 1,039
Self-citationWillms, E., Cabañas, C., Mäger, I., Wood, M. J. A., & Vader, P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00738 · Cited by 981
“Glioblastoma-derived EVs were found to directly bind to programmed cell death protein-1 (PD-1), ultimately leading to immune evasion through inhibition of T cell activation and proliferation (39).”
Exosomes in cancer development, metastasis, and immunity
Zhang, L., & Yu, D. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.04.004 · Cited by 870
“PDL1-containing EVs in the serum or plasma of glioblastoma patients were positively correlated with tumor burden [133].”
BackgroundContext-specific regulation of extracellular vesicle biogenesis and cargo selection
Dixson, A. C., Dawson, T. R., Di Vizio, D., & Weaver, A. M. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00576-0 · Cited by 791
Large-scale generation of functional mRNA-encapsulating exosomes via cellular nanoporation
Yang, Z., Shi, J., Xie, J., Wang, Y., Sun, J., Liu, T., Zhao, Y., Zhao, X., Wang, X., Ma, Y., et al. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0485-1 · Cited by 744
Morrissey, S. M., Zhang, F., Ding, C., Montoya-Durango, D. E., Hu, X., Yang, C., Wang, Z., Yuan, F., Fox, M., Zhang, H.-G., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.09.002 · Cited by 605
Extracellular vesicles in immunomodulation and tumor progression
Marar, C., Starich, B., & Wirtz, D. (2021) · Nature Immunology · doi:10.1038/s41590-021-00899-0 · Cited by 584
Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells
Keller, L., & Pantel, K. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0180-2 · Cited by 544
Glioblastoma stem cells: lessons from the tumor hierarchy in a lethal cancer
Gimple, R. C., Bhargava, S., Dixit, D., & Rich, J. N. (2019) · Genes & Development · doi:10.1101/gad.324301.119 · Cited by 514
“While immune checkpoint inhibitors targeting CTLA-4 and the PD-1/PD-L1 axis demonstrate remarkable efficacy in other cancers, their role in glioblastoma remains to be determined pending completion of clinical trials.”
BackgroundYamaguchi, H., Hsu, J.-M., Yang, W.-H., & Hung, M.-C. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00601-9 · Cited by 493
Shedding Light on Extracellular Vesicle Biogenesis and Bioengineering
Teng, F., & Fussenegger, M. (2021) · Advanced Science · doi:10.1002/advs.202003505 · Cited by 382
Mechanisms associated with biogenesis of exosomes in cancer
McAndrews, K. M., & Kalluri, R. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0963-9 · Cited by 394
“In addition, PD-L1 is packaged in melanoma, glioblastoma and breast cancerderived exosomes and is thought to contribute to immunosuppression and lack of response to PD-1 blockade [4, 49, 50].”
BackgroundThe role of exosomal PD-L1 in tumor progression and immunotherapy
Xie, F., Xu, M., Lu, J., Mao, L., & Wang, S. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1074-3 · Cited by 348
Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma
DeCordova, S., Shastri, A., Tsolaki, A. G., Yasmin, H., Klein, L., Singh, S. K., & Kishore, U. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01402 · Cited by 346
The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy
Lim, A. R., Rathmell, W. K., & Rathmell, J. C. (2020) · eLife · doi:10.7554/elife.55185 · Cited by 327
Glioblastoma Therapy: Past, Present and Future
Obrador, E., Moreno-Murciano, P., Oriol-Caballo, M., López-Blanch, R., Pineda, B., Gutiérrez-Arroyo, J., Loras, A., Gonzalez-Bonet, L., Martinez-Cadenas, C., Estrela, J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052529 · Cited by 271
Tracking the evolution of circulating exosomal‐PD‐L1 to monitor melanoma patients
Cordonnier, M., Nardin, C., Chanteloup, G., Derangere, V., Algros, M., Arnould, L., Garrido, C., Aubin, F., & Gobbo, J. (2020) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2019.1710899 · Cited by 262
Chiocca, E. A., Yu, J. S., Lukas, R. V., Solomon, I. H., Ligon, K. L., Nakashima, H., Triggs, D. A., Reardon, D. A., Wen, P., Stopa, B. M., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw5680 · Cited by 263
Self-citationIndoleamine 2,3‐dioxygenase 1 (IDO1): an up‐to‐date overview of an eclectic immunoregulatory enzyme
Pallotta, M. T., Rossini, S., Suvieri, C., Coletti, A., Orabona, C., Macchiarulo, A., Volpi, C., & Grohmann, U. (2022) · The FEBS Journal · doi:10.1111/febs.16086 · Cited by 238
Extracellular Vesicles and Their Roles in Cancer Progression
Chang, W.-H., Cerione, R. A., & Antonyak, M. A. (2021) · Methods in Molecular Biology · doi:10.1007/978-1-0716-0759-6_10 · Cited by 224
Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients
Li, C., Li, C., Zhi, C., Liang, W., Wang, X., Chen, X., Lv, T., Shen, Q., Song, Y., Lin, D., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-2101-2 · Cited by 233
New insights into extracellular vesicle biogenesis and function
Latifkar, A., Hur, Y. H., Sanchez, J. C., Cerione, R. A., & Antonyak, M. A. (2019) · Journal of Cell Science · doi:10.1242/jcs.222406 · Cited by 221
“…of highly aggressive cancer cells, which are enriched in PD-L1, can suppress the immune response and provide a protective barrier surrounding the tumor, engaging and inactivating T-cells before they are able to reach the cancer cells (Chen et al., 2018; Ricklefs et al., 2018; Poggio et al., 2019).”
BackgroundCharacterizing Extracellular Vesicles and Their Diverse RNA Contents
Veziroglu, E. M., & Mias, G. I. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00700 · Cited by 222
Harnessing the immune system in glioblastoma
Brown, N. F., Carter, T. J., Ottaviani, D., & Mulholland, P. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0258-8 · Cited by 223
Choi, D., Montermini, L., Jeong, H., Sharma, S., Meehan, B., & Rak, J. (2019) · ACS Nano · doi:10.1021/acsnano.9b04480 · Cited by 221
LSD1 deletion decreases exosomal PD-L1 and restores T-cell response in gastric cancer
Shen, D.-D., Pang, J.-R., Bi, Y.-P., Zhao, L.-F., Li, Y.-R., Zhao, L.-J., Gao, Y., Wang, B., Wang, N., Wei, L., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01557-1 · Cited by 200
“As represented by CD69, an activation marker of CD8+ T cells, anti-CD3/CD28 beads greatly increased CD69 expression [35], and there was obvious downregulation of CD69 in CD8+ T cells when treated with B-EXO, while B KO-EXO or blocking the effect of exosomal PD-L1 with a PD-L1 antibody or PD-1 recombinant rescued the s…”
BackgroundCheng, A. N., Cheng, L.-C., Kuo, C.-L., Lo, Y. K., Chou, H.-Y., Chen, C.-H., Wang, Y.-H., Chuang, T.-H., Cheng, S.-J., & Lee, A. Y.-L. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001372 · Cited by 206
Self-citationExosomes as mediators of immune regulation and immunotherapy in cancer
Kugeratski, F. G., & Kalluri, R. (2021) · The FEBS Journal · doi:10.1111/febs.15558 · Cited by 192
The updated role of exosomal proteins in the diagnosis, prognosis, and treatment of cancer
Wang, X., Huang, J., Chen, W., Li, G., Li, Z., & Lei, J. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00855-4 · Cited by 185
Shields, C. W., Wang, L. L., Evans, M. A., & Mitragotri, S. (2020) · Advanced Materials · doi:10.1002/adma.201901633 · Cited by 193
The Role of Extracellular Vesicles in the Hallmarks of Cancer and Drug Resistance
Xavier, C. P. R., Caires, H. R., Barbosa, M. A. G., Bergantim, R., Guimarães, J. E., & Vasconcelos, M. H. (2020) · Cells · doi:10.3390/cells9051141 · Cited by 172
“Glioblastoma miR-21, PD-L1 In vitro [104,105] Hepatocellular carcinoma lncRNA TUC339; miR-21 In vitro [106,107] Nasopharyngeal carcinoma miR-24-3p, galectin-9 In vivo, Patients Samples [108–110] Renal cell carcinoma Fas ligand In vitro [111] Osteosarcoma miR-675 In vitro [112] Gastric Cancer miR-27a In vivo; Patient s…”
BackgroundImmunosuppression in Glioblastoma: Current Understanding and Therapeutic Implications
Himes, B. T., Geiger, P. A., Ayasoufi, K., Bhargav, A. G., Brown, D. A., & Parney, I. F. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.770561 · Cited by 170
“Increasing evidence suggests that tumor-derived extracellular vesicles (EVs) are major mediators of tumor-induced immune suppression in GBM (84, 113).”
BackgroundExosomal PD-L1: Roles in Tumor Progression and Immunotherapy
Morrissey, S. M., & Yan, J. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.03.002 · Cited by 172
“Similar work in HNSCC also showed patients with recurrence during treatment had increases in the TEX/total exosome ratio as well as in the number of CD3(−)PD-L1+ exosomes from baseline [11].”
BackgroundResultInfluentialExosomes and extracellular vesicles: Rethinking the essential values in cancer biology
Yokoi, A., & Ochiya, T. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.032 · Cited by 167
Lee-Chang, C., Rashidi, A., Miska, J., Zhang, P., Pituch, K. C., Hou, D., Xiao, T., Fischietti, M., Kang, S. J., Appin, C. L., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0240 · Cited by 171
“This mechanism has been reported in GBM patients, where tumor-derived extracellular vesicles carrying PD-L1 on their surface can inhibit CD8þ T-cell activity (59).”
BackgroundTumor-Derived Extracellular Vesicles: Multifunctional Entities in the Tumor Microenvironment
Clancy, J. W., & D'Souza-Schorey, C. (2023) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-031521-022116 · Cited by 162
“…EVs including systematic suppression of antitumor immunity, increased tumor growth, conversion from PD-L1-negative to PD-L1-positive status, inhibition of cell killing and cell signaling in T cells, suppressed T cell proliferation, and reduced T helper 1 cell cytokine secretion (102-105).”
Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas
Aslan, K., Turco, V., Blobner, J., Sonner, J. K., Liuzzi, A. R., Núñez, N. G., De Feo, D., Kickingereder, P., Fischer, M., Green, E., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14642-0 · Cited by 162
Understanding extracellular vesicle diversity – current status
Greening, D. W., & Simpson, R. J. (2018) · Expert Review of Proteomics · doi:10.1080/14789450.2018.1537788 · Cited by 160
“Functionally, sMVs have been demonstrated to play a role in multi-drug resistance [71], immunosuppression [72,73], evasion of immune surveillance [74], and the development of cancer [75]; cancer stem cell-derived sMVs have been shown to be implicated in pre-metastatic niche formation [76].”
BackgroundBian, X., Xiao, Y.-T., Wu, T., Yao, M., Du, L., Ren, S., & Wang, J. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0973-7 · Cited by 160
“When glioblastoma PD-L1 was up-regulated by IFN-γ, EVs also showed some PD-L1 dependent inhibition of T cell activation [93].”
BackgroundThe Interplay between Glioblastoma and Its Microenvironment
Dapash, M., Hou, D., Castro, B. A., Lee-Chang, C., & Lesniak, M. S. (2021) · Cells · doi:10.3390/cells10092257 · Cited by 187
“Furthermore, EVs incorporating PD-L1 on their surface are able to inhibit T cell activation, further promoting the immunosuppressive environment of the TME [42].”
BackgroundYin, Z., Yu, M., Ma, T., Zhang, C., Huang, S., Karimzadeh, M. R., Momtazi‐Borojeni, A. A., & Chen, S. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001698 · Cited by 162
ICAM-1-mediated adhesion is a prerequisite for exosome-induced T cell suppression
Zhang, W., Zhong, W., Wang, B., Yang, J., Yang, J., Yu, Z., Qin, Z., Shi, A., Xu, W., Zheng, C., et al. (2022) · Developmental Cell · doi:10.1016/j.devcel.2022.01.002 · Cited by 146
Recent Progress in Isolation and Detection of Extracellular Vesicles for Cancer Diagnostics
Wang, W., Luo, J., & Wang, S. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201800484 · Cited by 149
Extracellular Vesicles in Glioblastoma Tumor Microenvironment
Yekula, A., Yekula, A., Muralidharan, K., Kang, K., Carter, B. S., & Balaj, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03137 · Cited by 148
“It has also been shown that PD-L1 DNA detected in the plasma of GBM patients correlated with tumor volume and can be used as a biomarker (87).”
BackgroundSelf-citationExploiting Exosomes in Cancer Liquid Biopsies and Drug Delivery
Fitts, C. A., Ji, N., Li, Y., & Tan, C. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201801268 · Cited by 138
Niu, M., Liu, Y., Yi, M., Jiao, D., & Wu, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.827921 · Cited by 161
Kooijmans, S. A. A., de Jong, O. G., & Schiffelers, R. M. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.03.017 · Cited by 139
The B7:CD28 family and friends: Unraveling coinhibitory interactions
Burke, K. P., Chaudhri, A., Freeman, G. J., & Sharpe, A. H. (2024) · Immunity · doi:10.1016/j.immuni.2024.01.013 · Cited by 155
Self-citationExtracellular vesicles and particles impact the systemic landscape of cancer
Lucotti, S., Kenific, C. M., Zhang, H., & Lyden, D. C. (2022) · The EMBO Journal · doi:10.15252/embj.2021109288 · Cited by 154
Fleming, V., Hu, X., Weller, C., Weber, R., Groth, C., Riester, Z., Hüser, L., Sun, Q., Nagibin, V. S., Kirschning, C. J., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0053 · Cited by 145
Krishnamachary, B., Cook, C. M., Kumar, A., Spikes, L. A., Chalise, P., & Dhillon, N. K. (2021) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12117 · Cited by 145
“Many studies have established the role of PD-L1-linked EVs in promoting an immunosuppressive environment and have suggested macrophages and dendritic cells may be a potential source of EV-PD-L1 (Chen et al., 2018; Ricklefs et al., 2018).”
BackgroundDissecting exosome inhibitors: therapeutic insights into small-molecule chemicals against cancer
Kim, J. H., Lee, C., & Baek, M. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00898-7 · Cited by 147
Maire, C. L., Fuh, M. M., Kaulich, K., Fita, K. D., Stevic, I., Heiland, D. H., Welsh, J. A., Jones, J. C., Görgens, A., Ricklefs, T., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab012 · Cited by 139
Self-citationComprehensive in vitro characterization of PD-L1 small molecule inhibitors
Ganesan, A., Ahmed, M., Okoye, I., Arutyunova, E. I., Babu, D., Turnbull, W. L., Kundu, J. K., Shields, J. A., Agopsowicz, K. C., Xu, L., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-48826-6 · Cited by 144
Ricklefs, F. L., Maire, C. L., Reimer, R., Dührsen, L., Kolbe, K., Holz, M., Schneider, E., Rissiek, A., Babayan, A., Hille, C., et al. (2019) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2019.1588555 · Cited by 133
“Beyond their value as biomarkers in cancer [3,9,10], EVs have further been postulated to play an active role in shaping the tumour microenvironment [2,11] and to have therapeutic potential [12–14].”
BackgroundMethodSelf-citationLiquid biopsy in gliomas: A RANO review and proposals for clinical applications
Soffietti, R., Bettegowda, C., Mellinghoff, I. K., Warren, K. E., Ahluwalia, M. S., de Groot, J., Galanis, E., Gilbert, M. R., Jaeckle, K. A., Rhun, É. L., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac004 · Cited by 139
“75,76 Other clinical applications of EVs for liquid biopsy in gliomas include the investigation of specific molecular alterations, such as EGFRvIII and IDH1 mutation proteins or miRNAs. mRNA of EGFRvIII was identified in serum EVs of 7/25 (28”
The biological implications of Yin Yang 1 in the hallmarks of cancer
Meliala, I. T. S., Hosea, R., Kasim, V., & Wu, S. (2020) · Theranostics · doi:10.7150/thno.43481 · Cited by 135
“Furthermore, YY1 might positively regulate the expression of programmed death ligand 1 (PD-L1), whose expression is correlated with poor clinical response to cell-mediated anti-tumor therapy, through crosstalk between YY1 and PD-L1 signaling pathways [119-121].”
BackgroundLiquid Biopsy in Glioblastoma: Opportunities, Applications and Challenges
Saenz‐Antoñanzas, A., Auzmendi-Iriarte, J., Carrasco‐García, E., Moreno‐Cugnon, L., Ruiz, I., Villanúa, J., Egaña, L., Otaegui, D., Samprón, N., & Matheu, A. (2019) · Cancers · doi:10.3390/cancers11070950 · Cited by 159
“PD-L1 expression has been found on the surface of glioblastoma-derived EVs [45].”
BackgroundExosomal PD‐L1 functions as an immunosuppressant to promote wound healing
Su, D., Tsai, H., Xu, Z., Yan, F., Wu, Y., Xiao, Y., Liu, X., Wu, Y., Parvanian, S., Zhu, W., et al. (2019) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2019.1709262 · Cited by 134
Breaking through the glioblastoma micro-environment via extracellular vesicles
Simon, T., Jackson, E., & Giamas, G. (2020) · Oncogene · doi:10.1038/s41388-020-1308-2 · Cited by 120
Ambattu, L. A., Ramesan, S., Dekiwadia, C. D., Hanssen, E. G., Li, H., & Yeo, L. Y. (2020) · Communications Biology · doi:10.1038/s42003-020-01277-6 · Cited by 130
Hajihosseini, R., Asef‐Kabiri, L., Yousefi, H., Sarvnaz, H., Salehi, M., Akbari, M. E., & Eskandari, N. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01376-w · Cited by 131
“Due to the pivotal role that TDEs play in multiple aspects of tumor development and growth, such as proliferation, angiogenesis, metastatic niche formation and immune escape, a strong interest has emerged in recent years to selectively inhibit the generation/release of tumor exosomes as an adjunctive therapy for cance…”
BackgroundLiu, S., Liu, J., Li, H., Mao, K., Wang, H., Meng, X., Wang, J., Wu, C., Chen, H., Wang, X., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121645 · Cited by 122
Chandran, V. I., Welinder, C., Månsson, A., Offer, S., Freyhult, E., Pernemalm, M., Lund, S. M., Pedersen, S., Lehtiö, J., Marko‐Varga, G., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2946 · Cited by 120
“In GBM, a pilot study from our group suggested that the plasma EV (plEV) proteome reflects the tumor oxygenation status (10), whereas others have shown that serum and cerebrospinal fluid derived EVs correlate with EGFR expression and mutation status, tumor size, and treatment response (11-18).”
BackgroundThe cancer exosomes: Clinical implications, applications and challenges
Tang, Z., Li, D., Hou, S., & Zhu, X. M. (2019) · International Journal of Cancer · doi:10.1002/ijc.32762 · Cited by 118
Immunotherapy for Glioblastoma: Adoptive T-cell Strategies
Choi, B. D., Maus, M. V., June, C. H., & Sampson, J. H. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1625 · Cited by 121
Targeted inhibition of tumor-derived exosomes as a novel therapeutic option for cancer
Li, Y., Chen, Z.-K., Duan, X., Zhang, H., Xiao, B.-L., Wang, K.-M., & Chen, G. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00856-3 · Cited by 117
Zhang, H., Zhou, Y., Cui, B., Liu, Z., & Shen, H. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110086 · Cited by 120
Lee, C., Bae, J.-H., Choe, E., Park, J., Park, S., Cho, H. J., Song, B., & Baek, M. (2022) · Theranostics · doi:10.7150/thno.68864 · Cited by 112
“EV PD-L1 and decreased efficacy of anti-PD-1/ PD-L1 therapy are causally related [4, 6, 12, 15-18].”
BackgroundInfluentialExtracellular Vesicles in neural cell interaction and CNS homeostasis
Schnatz, A., Müller, C., Brahmer, A., & Krämer‐Albers, E. (2021) · FASEB BioAdvances · doi:10.1096/fba.2021-00035 · Cited by 119
Extracellular vesicles versus lipid nanoparticles for the delivery of nucleic acids
Bader, J., Brigger, F., & Leroux, J. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115461 · Cited by 114
Sun, Y., Luo, J., Chen, Y., Cui, J., Lei, Y., Cui, Y., Jiang, N., Jiang, W., Chen, L., Chen, Y., et al. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106198 · Cited by 111
Extracellular Vesicle-Mediated Communication between the Glioblastoma and Its Microenvironment
Matarredona, E. R., & Pastor, A. M. (2019) · Cells · doi:10.3390/cells9010096 · Cited by 97
Biology and therapeutic potential of extracellular vesicle targeting and uptake
Ripoll, L., Zickler, A. M., Vader, P., Andaloussi, S. E., Verweij, F. J., & van Niel, G. (2026) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-025-00922-4 · Cited by 123
Soluble B7-CD28 Family Inhibitory Immune Checkpoint Proteins and Anti-Cancer Immunotherapy
Khan, M. S. I., Arooj, S., & Wang, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.651634 · Cited by 106
Exosomal PD‐L1: New Insights Into Tumor Immune Escape Mechanisms and Therapeutic Strategies
Zhou, K., Guo, S., Li, F., Sun, Q., & Liang, G. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.569219 · Cited by 99
Immunotherapy in glioblastoma treatment: Current state and future prospects
Pinheiro, S. L. R., Lemos, F. F. B., Marques, H. S., Luz, M. S., Silva, L. G. D. O., dos Santos, C. F. S. M., Evangelista, K. D. C., Calmon, M. S., Loureiro, M. S., & de Melo, F. F. (2023) · World Journal of Clinical Oncology · doi:10.5306/wjco.v14.i4.138 · Cited by 111
Nicolini, A., Ferrari, P., & Biava, P. M. (2021) · Cancers · doi:10.3390/cancers13040822 · Cited by 102
“In the other [99], PD-L1 carrying EVs, which were present in the serum or plasma and derived from glioblastoma cells, were directly correlated with the tumour burden.”
BackgroundCharacterization of single microvesicles in plasma from glioblastoma patients
Fraser, K. B., Jo, A., Giedt, J., Vinegoni, C., Yang, K. S., Peruzzi, P. P., Chiocca, E. A., Breakefield, X. O., Lee, H., & Weissleder, R. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy187 · Cited by 100
Self-citationKo, J., Wang, Y., Carlson, J. C. T., Marquard, A., Gungabeesoon, J., Charest, A., Weitz, D., Pittet, M. J., & Weissleder, R. (2020) · Advanced Biosystems · doi:10.1002/adbi.201900307 · Cited by 97
Self-citationmicroRNAs (miRNAs) in Glioblastoma Multiforme (GBM)—Recent Literature Review
Makowska, M., Smolarz, B., & Romanowicz, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043521 · Cited by 101
Kang, J. H., Jung, M., Choudhury, M., & Leof, E. B. (2019) · The FASEB Journal · doi:10.1096/fj.201902354r · Cited by 102
Emerging Role of Glioma Stem Cells in Mechanisms of Therapy Resistance
Eckerdt, F., & Platanias, L. C. (2023) · Cancers · doi:10.3390/cancers15133458 · Cited by 110
Habashy, K. J., Mansour, R., Moussalem, C., Sawaya, R., & Massaad, M. J. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01864-w · Cited by 95
“Similarly, GBMs release extracellular vesicles that contain PD-L1, which inhibits T cells activation and proliferation [125].”
BackgroundIsolation and Analysis of Plasma-Derived Exosomes in Patients With Glioma
Cumba Garcia, L. M., Peterson, T. E., Cepeda, M. A., Johnson, A. J., & Parney, I. F. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00651 · Cited by 92
“GBM-EV PD-L1 expression has been reported by others (35) and been demonstrated in vitro in our hands (data not shown).”
BackgroundHypoxia within the glioblastoma tumor microenvironment: a master saboteur of novel treatments
Feldman, L. A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1384249 · Cited by 103
“…target tumor cells, the microenvironment may suppress their activity and proliferation by expressing inhibitory cell-surface molecules (such as PD-L1, CD95) (88) or by releasing immunosuppressive tumor-derived soluble factors and cytokines (such as prostaglandin E2, IL6, IL10, and TGF b ) (89).”
BackgroundZhao, X., Yuan, C., Wangmo, D., & Subramanian, S. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.04.036 · Cited by 96
Himes, B. T., Peterson, T. E., de Mooij, T., Garcia, L. M. C., Jung, M.-Y., Uhm, S., Yan, D., Tyson, J., Jin-Lee, H. J., Parney, D., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa029 · Cited by 92
Extracellular and nuclear PD-L1 in modulating cancer immunotherapy
Xiong, W., Gao, Y., Wei, W., & Zhang, J. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.03.003 · Cited by 93
Busatto, S., Morad, G., Guo, P., & Moses, M. A. (2021) · FASEB BioAdvances · doi:10.1096/fba.2021-00045 · Cited by 98
Qiu, Z., Zhao, L., Shen, J., Liang, Z., Wu, Q., Yang, K., Min, L., Gimple, R. C., Yang, Q., Bhargava, S., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1848 · Cited by 93
Self-citationShen, T., Huang, Z., Shi, C., Pu, X., Xu, X., Wu, Z., Ding, G., & Cao, L. (2020) · The FASEB Journal · doi:10.1096/fj.201902186r · Cited by 90
Extracellular Vesicles as Next-Generation Diagnostics and Advanced Therapy Medicinal Products
Stawarska, A., Bamburowicz‐Klimkowska, M., Rundén‐Pran, E., Dušinská, M., Cimpan, M. R., Ríos-Mondragón, I., & Grudziński, I. P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126533 · Cited by 95
“Research focuses on understanding the role of exosomes in promoting inflammation within the tumor microenvironment, carrying pro-inflammatory signals that contribute to a pro-tumorigenic inflammatory milieu [161,162].”
BackgroundGuan, L., Wu, B., Li, T., Beer, L. A., Sharma, G., Li, M., Lee, C. N., Liu, S., Yang, C., Huang, L., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31713-6 · Cited by 89
“VHS FYVE UIM PSAP CB 1-1 39 15 5-2 21 25 7-2 77 34 8-3 51 70 4-7 77 CC 46 9-5 53 i (1-777) 100 70”
A good start of immunotherapy in esophageal cancer
Zhao, Q., Yu, J., & Meng, X. (2019) · Cancer Medicine · doi:10.1002/cam4.2336 · Cited by 98
Metadata
- Authors
- Ricklefs, F. L., Alayo, Q., Krenzlin, H., Mahmoud, A. B., Speranza, M. C., Nakashima, H., Hayes, J. L., Lee, K., Balaj, L., Passaro, C., Rooj, A. K., Krasemann, S., Carter, B. S., Chen, C. C., Steed, T., Treiber, J., Rodig, S., Yang, K., Nakano, I., Lee, H., Weissleder, R., Breakefield, X. O., Godlewski, J., Westphal, M., Lamszus, K., Freeman, G. J., Bronisz, A., Lawler, S. E., & Chiocca, E. A.
- Affiliations
- Brigham and Women's Hospital (US)
- University of California, Berkeley (US)
- Massachusetts General Hospital (US)
- University Medical Center Hamburg-Eppendorf (DE)
- University of California San Diego (US)
- Comprehensive Cancer Center, University of Birmingham, Birmingham, AL 35294, USA.
- Harvard University (US)
- Corresponding author
- Lawler, Sean E.
- Chiocca, E. Antonio
- ORCID
- Ricklefs, Franz L.
- Alayo, Quazim
- Krenzlin, Harald
- Mahmoud, Ahmad B.
- Speranza, Maria C.
- Nakashima, Hiroshi
- Hayes, Josie L.
- Lee, Kyungheon
- Balaj, Leonora
- Passaro, Carmela
- Rooj, Arun K.
- Krasemann, Susanne
- Carter, Bob S.
- Chen, Clark C.
- Steed, Tyler
- Treiber, Jeffrey
- Rodig, Scott
- Yang, Katherine
- Nakano, Ichiro
- Lee, Hakho
- Weissleder, Ralph
- Breakefield, Xandra O.
- Godlewski, Jakub
- Westphal, Manfred
- Lamszus, Katrin
- Freeman, Gordon J.
- Bronisz, Agnieszka
- Lawler, Sean E.
- Chiocca, E. Antonio
- Venue
- Science Advances
- Published
- 2018-03-02
- Volume
- 4
- Issue
- 3
- Pages
- eaar2766-eaar2766
- ISSN
- 2375-2548 (ISSN-L)
- PMC
- PMC5842038
- OpenAlex
- W2793992337
- Cited by
- 610
- References
- 42
- Citations by year
- 2026: 48 · 2025: 68 · 2024: 76 · 2023: 76 · 2022: 85 · 2021: 111 · 2020: 75 · 2019: 56 · 2018: 15
- FWCI
- 22.86
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Science Advances (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- National Institutes of Health (CA176203-01A1)
- National Cancer Institute (P01 CA69246)
- Deutsche Forschungsgemeinschaft (RI 2616/1-1, RI 2616/2-1)
- National Institute of Health (NCI P01 CA69246)
- American-Italian Cancer Foundation Post-doctoral Research Fellowship
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Keywords
- glioblastoma, PD-L1, extracellular vesicles, immune evasion, antitumor immunity, tumor microenvironment, biomarkers
- MeSH terms
- Extracellular Vesicles, Antigens, Neoplasm, Brain Neoplasms, Glioblastoma, Humans, Interferon-gamma, Lymphocyte Activation, Receptors, Antigen, T-Cell, T-Lymphocytes, Neoplastic Stem Cells, Up-Regulation, Gene Expression Regulation, Neoplastic, Cell Line, Tumor, Immune Evasion, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.